BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B

BeOne Medicines Ltd.

2026-Q1 EPS reported $0.15 revenue$1,513,438,000

Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)
R&D total $2.15B, up 10% YoY; largest pipeline: sonrotoclax $176.7M, BRUKINSA $97.6M
Key product production 6.27M vials, sales 5.99M vials; inventory 2.91M vials at Dec 31, 2025
U.S. GAAP vs PRC GAAP differences: stock compensation and lease accounting treatments vary

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.